The role of genetics in diagnosis and treatment of mood disorders Alessandro Serretti, MD, PhD Institute of Psychiatry University of Bologna Italy.

Slides:



Advertisements
Similar presentations
David A Collier Professor of Neuropsychiatric Genetics Institute of Psychiatry Copy Number Variation in neurodevelopmental disorders:
Advertisements

Genes that affect novelty seeking behavior
Genetics and Neuroimaging:
Genetic research designs in the real world Vishwajit L Nimgaonkar MD, PhD University of Pittsburgh
Introduction to genomes & genome browsers
Genetic Inheritance and Behavior IB Psychology from Levels of Analysis IB Psychology from Levels of Analysis.
Mapping Genetic Risk of Suicide Virginia Willour, Ph.D.
Presentation Title February 23, 2011 Establishing Clinical-grade Assays for Support of Drug Trials May 3, 2012 Patrick Hurban Expression Analysis.
Polymorphisms: Clinical Implications By Amr S. Moustafa, M.D.; Ph.D. Assistant Prof. & Consultant, Medical Biochemistry Dept. College of Medicine, KSU.
Psychopharmacogenomics in Child & Adolescent Psychiatry
Dr. Almut Nebel Dept. of Human Genetics University of the Witwatersrand Johannesburg South Africa Significance of SNPs for human disease.
Neurotransmission and the CNS BY PROF. Azza El-Medany.
The Pursuit of Better Medicines through Genetic Research Terri Arledge, DVM US Department Head Drug Development Genetics.
Réunion Ambulatoires SAS,  Similarly, a statistically significant MADRS reduction over time was found (F=156.2, p 800 mg/day) and low (
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
TODAY…. TOMORROW…. trials and errors diagnosis effective treatment
Introduction Basic Genetic Mechanisms Eukaryotic Gene Regulation The Human Genome Project Test 1 Genome I - Genes Genome II – Repetitive DNA Genome III.
Presented by: Caitlin Cleary. Depression Depression is among the top five leading causes of disability and disease burden throughout the world Stressful.
Understanding Genetics of Schizophrenia
Genetic Analysis in Human Disease. Learning Objectives Describe the differences between a linkage analysis and an association analysis Identify potentially.
Adapted from Lesch & Mossner, Biol Psychiatry ’-HT transporter promoter polymorphism (5’-HTTLPR,17q11) (SLC6A4)
Epigenome 1. 2 Background: GWAS Genome-Wide Association Studies 3.
Foundations of Genetic Research: A Primer How can something so tiny make such a big difference? Rebecca A. Lundwall Psychology Department Brigham Young.
 List TEN goals that you have.  Complete TEN sentences starting with “I am….” DO NOW!
Association study of 5-HT2A genes with schizophrenia in the Malaysian population: A Multiethnic Meta- analysis Study Shiau Foon Tee* 1, Tze Jen Chow 1,
The Pie of Schizophrenia (Theoretical: Early Molecular Biology)
Genetics of Alcoholism Laura Jean Bierut, MD Washington University.
Apo E and pharmacogenetics: tailoring cures to the patient Jose Ordovas PhD Professor/Senior Scientist JM-USDA-Human Nutrition Research Center on Aging,
The Early Days of an Investigator in WIHS: Grants and Projects By Bani Tamraz, Pharm.D., Ph.D. Associate Clinical Professor School of Pharmacy.
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Two RANTES gene polymorphisms and their haplotypes in patients with myocardial infarction from two Slavonic populations Two RANTES gene polymorphisms and.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: VEGFA and VEGFR1 and Response to Anti-VEGF Hagstrom SA, Ying G, Pauer GJT, et.
Plasticity and Promise: A New Era in Brain Research and Psychiatry
By: Dr. M. M. O. Okonji FRCPsych. (UK) Consultant Psychiatrist.
Project 5: Molecular Genetics and Pharmacogenetics W. Maier, M. Ackenheil, M. Rietschel.
mRNA post-transcriptional regulation
Psychiatric Disorder: Is It All In The Genes? Why might a disorder run in families? §Shared genes §Shared environment §A combination of the two.
THE DEFLATION OF GENOMIC BUBBLE AND THE HOPES OF EPIGENETICS The Pathogenesis of Diseases from Genetic and Genomic Point of View - 4.
They deserve personalized treatment Your patients are unique.
5-HT T LPR S ALLELE SHORTY SADNESS. DEPRESSION (MAJOR DEPRESSIVE DISORDER) Depressed mood most of the day, nearly every day, as indicated by either subjective.
Medication Strategies: Switch vs. Augmentation Robert K. Schneider, MD Assistant Professor Departments of Psychiatry, Internal Medicine and Family Practice.
How Genetic Variants Impact the Safety and Effectiveness of Drugs Pharmacogenetics © PGXL Laboratories.
Computational Biology and Genomics at Boston College Biology Gabor T. Marth Department of Biology, Boston College
Big Data in Biology: A focus on genomics. Bioinformatics and Genomics O Applications: O Personalized cancer medicines O Disease determination O Pathway.
Human Genomics Higher Human Biology. Learning Intentions Explain what is meant by human genomics State that bioinformatics can be used to identify DNA.
The biology of the brain and its implications for health care Barbara Franke, PhD Departments of Human Genetics & Psychiatry Donders Institute for Brain,
The NIMH Research Domain Criteria Initiative (RDoC): A Framework for Psychopathology Research February 20, 2014 Jill Heemskerk, PhD Deputy Director, Division.
Obsessive Compulsive Disorder and SLC6A4 Maisie Steinbrink m o.
1 Pharmacogenetics of Antipsychotic Drug Response Anil K. Malhotra, MD The Zucker Hillside Hospital Glen Oaks, New York The Albert Einstein College of.
1 Finding disease genes: A challenge for Medicine, Mathematics and Computer Science Andrew Collins, Professor of Genetic Epidemiology and Bioinformatics.
Pharmacogenetics/Pharmacogenomics. Outline Introduction  Differential drug efficacy  People react differently to drugs Why does drug response vary?
Looking Within Human Genome King abdulaziz university Dr. Nisreen R Tashkandy GENOMICS ; THE PIG PICTURE.
What should a psychiatrist know about genetics?
New research areas in personalised medicines
Pharmacogenetics in Obsessive-compulsive Disorder
MPI Psychiatry Munich Elisabeth Binder MPI Psychiatry Munich
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability  Larry Culpepper, MD, MPH, Philip.
Considering depression characteristics and antidepressants in the inflammation-depression relationship Nicole Vogelzangs Department of Psychiatry /
The Evaluation of CYP2D6, CYP2C9 and CYP2C19 Polymorphisms for Personalized Medicine in Psychiatry Patients Ebru DÜNDAR YENILMEZ1, Onur KARAYTUG2, Lut.
An Electronic Medical Record Based Pharmacogenetic Study
Genetic Testing for the Clinician
Dr Gayan Perera Epidemiologist
“Advances in Psychiatry of Japan”
The Evaluation of CYP2D6, CYP2C9 and CYP2C19 Polymorphisms for Personalized Medicine in Physiciatry Patients Ebru DUNDAR YENILMEZ1, Onur KARAYTUG2, Lut.
Pharmacogenetic effects on pharmacokinetics and pharmacodynamics
Gene Hunting: Design and statistics
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability  Larry Culpepper, MD, MPH, Philip.
Lurasidone Flavio Guzmán, MD.
Psychiatric Disorders: Diagnosis to Therapy
Psychiatric Disorders: Diagnosis to Therapy
Presentation transcript:

The role of genetics in diagnosis and treatment of mood disorders Alessandro Serretti, MD, PhD Institute of Psychiatry University of Bologna Italy

Genetics of mood disorders  Is genetics important for MD?  Is genetics useful for MD diagnosys?  Is genetics important for MD treatment?  Is genetics useful for MD treatment?

Genetics of mood disorders  Is genetics important for MD?  Is genetics useful for MD diagnosys?  Is genetics important for MD treatment?  Is genetics useful for MD treatment?

Morbid Risk in Bipolar Disorder %

Morbid Risk in Major Depressive Disorder %

Genetics of mood disorders  Is genetics important for MD? Yes  Is genetics useful for MD diagnosys?  Is genetics important for MD treatment?  Is genetics useful for MD treatment?

Genetics of mood disorders  Is genetics important for MD? Yes  Is genetics useful for MD diagnosys?  Is genetics important for MD treatment?  Is genetics useful for MD treatment?

%? ?

Genetics of mood disorders  Is genetics important for MD? Yes  Is genetics useful for MD diagnosys? Not as we may think! Plasticity  Is genetics important for MD treatment?  Is genetics useful for MD treatment?

Genetics of mood disorders  Is genetics important for MD? Yes  Is genetics useful for MD diagnosys? Not as we may think! Plasticity  Is genetics important for MD treatment?  Is genetics useful for MD treatment?

diagnosis trials and errors effective treatment TODAY….

diagnosis trials and errors effective treatment TODAY…. TOMORROW…. tailor made

Genetic Variation  Unrelated individuals are (only) 99% genetically similar.  There is about a 7 million bp difference between any two non-related individuals.  Plus CNVs, epigenetics, expression controls…  This explains interindividual variability  Hair color, weight and …. disease liability, drug response.

Pharmacogenetic studies (Medline )

VARIATIONS IN DRUG RESPONSE GENE ß2-ADREN. CETP D2, D3, 5HT2 APOE4 RYANODINE PROTHROMBIN NET Her2/neu DRUG ALBUTEROL PRAVASTATIN ANTIPSYCHOTICS TACRINE HALOTHANE CONTRACEPTIVES ATOMOXETINE TRASTUZUMAB EFFECT Asthma response Atherosclerosis resp. Response-Side eff. Alzheimer resp. Malignant hyperthermia Thrombosis Response (Ramoz 2009) Efficacy/Tolerance

GENETICPOLYMORPHISMS PharmacokineticPharmacodynamic TransportersTransporters Plasma protein bindingPlasma protein binding MetabolismMetabolism ReceptorsReceptors Ion channelsIon channels EnzymesEnzymes Immune moleculesImmune molecules

u HTTLPR u SERT-STin2 u 5HT1A C-1019G u 5-HT1B u 5HT2A T102C u 5HT2A G1438A u 5HT2C u 5HT6 C267T u TPH A218C TPH2 u NET T-182C u NET G1287A u COMT u MAOA u DRD2 S311C u DRD4 VNTR u ACE I/D polymorphism u G-protein beta3 C825T u ADRB1 G1165C u CRHR1 u NOS C276T u IL-1beta C511T u DTNBP1 u FKBP5 u CLOCK Genes investigated in the short term u MDNF u DTNBP1 u nNOS u IL-1beta u APOE u MDR1P-gp u A-161T

REGULATORY VARIANT OF 5-HT TRANSPORTER A functional polymorphism in the transcriptional control region upstream of the 5-HTT coding sequence (5-HTTLPR) has been reported (Heils et al., 1996).

5-HTTLPR variants explained 7% of the variance of antidepressant efficacy

HTTLPR l variant associated with better outcome and side effects in caucasians, conflicting in asians (“flip-flop” Lin, 2007) Possibly through a complex and indirect effect Multiple effects both in normals and patients (Serretti, 2006) Further variants control its effects HTTLPR - Conclusions

HTTLPR l variant associated with better outcome in caucasians Possibly through a complex and indirect effect Multiple effects both in normals and patients (Serretti, 2006) Further variants control its effects HTTLPR - Conclusions

5-HTTLPR variations…… Broad influence of a single gene on a range of aspects Temperament Stress reactivity Anatomical change Mood disorders Response to antidepressants Poor serotonin pathway plasticity

Harro J (2009): The brain prepared to become anxious: predisposing neurobiology in animals and humans. Eur. Neuropsychopharm. 19:S113.

HTTLPR l variant associated with better outcome in caucasians Possibly through a complex and indirect effect Multiple effects both in normals and patients (Serretti et al., Curr Drug Targ, 2006) Further variants control its effects HTTLPR - Conclusions

 16-A  16-D  16-F tgcacccccagcatcccccc tgcacccccggcatcccccc tgcactcccagcatcccccc Types of 16th repeat (*l) Nakamura, 2000; Goldman, 2004

Studies with at least two independent replications

(Binder et al., 2004)FKBP5 Assoc. with resp. in 2 indep. samples (Tsai et al., 2007)FKBP5No association (van Rossum et al., 2006)NR3Cl ER22/23EK Associated with response (Papiol et al., 2007)FKBP5rs trend with response (p=0.09) (Lekman et al., 2008)FKBP5rs Assoc with remission (Kirchheiner et al., 2008)FKBP5rs and rs associated with response (venlafaxine and drug combination) FKBP5

BDNF

Dysbindin Studies with at least two independent replications

Dysbindin associated with SSRI antidepressant efficacy

DTNBP1 haplotype analysis for rs , rs and rs , on final MADRS covariated for baseline scores (haplotypes frequency>1%) P=

DYSBINDIN GENE (DTNBP1) IN mood disorders: ASSOCIATION WITH CLINICAL RESPONSE TO SSRIs Arias, B; Serretti, A; Mandelli, L; Gastó, C; Catalán, R; Di Ronchi, D; Fañanás, L. Pharmacogenet Genomics, In Press

Two-way repeated measures ANOVA for rs760761

P-glycoprotein - MDR1 Studies with at least two independent replications

MDR1

(Paddock, 2007)GRIK4rs assoc. with remiss. p=.001 (Gau, 2007) p75 NTR S250L assoc. with response p=.039 GRIK4

u HTTLPR u SERT-STin2 u 5HT1A C-1019G u 5-HT1B u 5HT2A T102C u 5HT2A G1438A u 5HT2C u 5HT6 C267T u TPH1 A218C u TPH1 A218C TPH2 u NET T-182C u NET G1287A u COMT u MAOA u DRD2 S311C u DRD4 VNTR u ACE I/D polymorphism u G-protein beta3 C825T u ADRB1 G1165C u CRHR1 u NOS C276T u IL-1beta C511T u FKBP5 u CLOCK Genes investigated in the short term u MDNF u DTNBP1 u nNOS u IL-1beta u APOE u MDR1P-gp u GRIK4 Different target of SSRI Different Plasticity Different SSRI availability in the brain Glutamate modulation

Some gene variants influence antidepressant effects But…

Is antidepressant a unitary effect? And… Do genes influence only one behavioral feature?

CLOCK 3111T/C Broad influence of a single gene on a range of aspects Temperament Insomnia Diurnal Preference Mood fluctuations Response to antidepressants

Genetics of mood disorders  Is genetics important for MD? Yes  Is genetics useful for MD diagnosys? Not as we may think! Plasticity  Is genetics important for MD treatment? Yes  Is genetics useful for MD treatment?

Genetics of mood disorders  Is genetics important for MD? Yes  Is genetics useful for MD diagnosys? Not as we may think! Plasticity  Is genetics important for MD treatment? Yes  Is genetics useful for MD treatment? Yes, but in a complex way

Some gene variants influence antidepressant effects and other features Can we use them in everyday clinical practice?

NO

NOT YET

Pharmacogenetics: problematic issues…and possible solutions Low variance explained by polymorphisms (HTTLPR=2.8%, TPH=2.7%, Gß3=1.2%)  Other variables influence drug response: Life events, social support, temperament, hormons…and should be included in the model! Neural Network? Epigenetic factors, CNV, Splicing, Regional expression, gene interactions…should be controlled with multivariate or neural network models. Drug response may differ across episodes…longer follow up

Would be the puzzle the actual image of reality? adherence - compliance social support stressful events personality Epigenetic factors gene interactions HormonsHormons GenomicsGenomics ProteomicsProteomics

Kansai Medical University, Japan Prof. Toshihiko Kinoshita Masaki Kato MD The Catholic University of Korea College of Medicine, South Korea Prof. Chi-Un Pae Universitat de Barcelona, Spain Prof. Lourdes Fananas Barbara Arias PhD Univerza V Ljubljani - University Of Ljubljana, Slovenia Prof. Vita Dolzan Principal Collaborating Centers Athens University, Greece Prof. Yoannis Liappas Antonis Politis MD Petros Malitas MD University of Toronto, Canada Prof. Jim Kennedy Daniel Muller MD Ludwig-Maximilians-Universität München, Germany Prof. Dan Rujescu Ina Giegling PsyD

Psychiatric Genetic Unit, Institute of Psychiatry, University of Bologna, Italy Alessandro Serretti MD PhDLaura Mandelli PsyD Raffaella Calati PsyD, PhD Sara Gibiino Diana De Ronchi MD PhD Antonio Drago MD Alberto Chiesa MD Martina Forlani